Referências

1. Gossec L, et al. Ann Rheum Dis 2024;83:706–19.
2. Ramiro S, et al. Ann Rheum Dis 2023;82:19–34.
3. Bula do produto Taltz® (ixequizumabe). Disponível em: https://consultas.anvisa.gov.br/#/bulário/q/?nomeProduto=Taltz® . Acesso em: 17 dez. 2024.
4. Mease PJ, et al. Ann Rheum Dis. 2020;79:123–131.
5. Dougados M, et al. Ann Rheum Dis. 2020;79(2):176-185.
6. Van der Heijde D, et al. Lancet. 2018;392:2441-2451.
7. Deodhar AA, et al. Arthritis Rheumatol. 2019;71:599-611.
8. Deodhar AA, et al. Lancet. 2020;395:53-64.
9. Smolen JS, et al. Ann Rheum Dis. 2020;79(10):1310-1319.
10. Smolen JS, et al. Rheumatol Ther. 2020;7(4):1021-1035.
11. Heijde DV, et al. J Rheumatol. 2022 Mar;49(3):265-273.
12. Van der Heijde D, et al. POS0918. ARD 2021;80(Suppl 1):720.
13. Liu L, et al. J Inflamm Res. 2016;9:39-50.
14. Raychaudhuri SK, et al. Clin Rheumatol. 2015;34:1019-1023.
15. Taams LS, et al. Nat Rev Rheumatol. 2018;14:453-466.
16. Raychaudhuri SP, et al. Mol Cell Biochem. 2012;359:419-429.
17. De Vlam K, et al. Acta Derm Venereol. 2014;94:627-634.
18. Mease P, et al. EMJ Rheumatol. 2015;2:55-64.
19. Kehl AS, et al. Arthritis Rheumatol. 2016;68:312-322.
20. Raychaudhuri SP, Raychaudhuri SK. Arthritis Res Ther. 2017;19:51.
21. Suzuki E, et al. Autoimmun Rev. 2014;13:496-502.
22. Osta B, et al. Front Immunol. 2014;5:48.
23. Lee Y. BMB Rep. 2013;46:479-483.
24. Onishi RM, Gaffen SL. Immunology. 2010;129:311-321.

25. Caetano-Lopes J, et al. Autoimmun Rev. 2009;8:250-255.
26. Bula do produto Cosentyx® (secuquinumabe). Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=COSENTYX . Acesso em: 17 dez. 2024.
27. Tahir H, et al. Poster presented at the International Federation of Psoriasis Associations, 2024. Poster 109. Disponível em: https://assets.ctfassets.net/mpejy6umgthp/7nvD4yNi5Hj5tFGuyqw6aE/9c4f375260814fbc43974f8c8560bc77/Tahir_IFPA_2024_Supplemental_Materials.pdf . Acesso em: 17 dez. 2024.
28. Morel J, et al. Poster presented at the International Federation of Psoriasis Associations, 2024. Poster 110. Disponível em: https://assets.ctfassets.net/mpejy6umgthp/49DrpkCfFSrWmdufs2BCiv/357db62b1df65161a77c1851a8040baf/Morel_IFPA_2024_Supplemental_Materials.pdf . Acesso em: 17 dez. 2024.
29. Braun J, et al. RMD Open. 2022;8:e002165.
30. Landewé RB, et. al. Ann Rheum Dis. 2021;80:1022–30.
31. Xue Y, et al. Curr Rheumatol Rep. 2022;24(8):247-58.
32. Mease P, et al. Ann Rheum Dis. 2017;76:79-87.
33. Nash M, et al. Lancet. 2017;389:2317-2327.
34. McGonagle D, et al. Rheumatology (Oxford) 2024 Feb 10:keae060. doi: 10.1093/rheumatology/keae060. Publicado online antes da versão impressa.
35. Coates LC, et al. Nat Rev Rheumatol 2022;18:465–79.
36. Schoels MM, et al. Ann Rheum Dis 2016;75:811-8.
37. EMEA. Janus kinase inhibitors - referral. Disponível em: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinaseinhibitors-jaki# . Acesso em: 17 dez. 2024.
38. Tahir H, et al. Poster presented at the International Federation of Psoriasis Associations, 2024. Poster 110. Disponível em: https://assets.ctfassets.net/mpejy6umgthp/49DrpkCfFSrWmdufs2BCiv/357db62b1df65161a77c1851a8040baf/Morel_IFPA_2024_Supplemental_Materials.pdf . Acesso em: 17 dez. 2024.

39. Deodhar A, et al. Arthritis Res Ther 2024;26:49.
40. Rudwaleit M, et al. Arthritis Rheum 2009;60:717–27.
41. Lorenzin M, et al. Ther Adv Musculoskelet Dis 2020;12:1759720X20934277.
42. Spoorenberg A, et al. Rheumatology (Oxford) 2005;44:789–95.
43. Rudwaleit M, et al. Ann Rheum Dis 2004;63:665–70.
44. Vastesaeger N, et al. Ann Rheum Dis 2011;70:973–81.
45. Maksymowych WP, et al. Rheumatol 2022;61:4324–34.
46. Kong N, et al. Ann Rheum Dis. 2024;83(suppl 1):895-96.
47. Zou H, et al. Ann Rheum Dis. 2024;83 (Suppl 1):1763–64.
48. Deodhar A, et al. J Rheumatol 2023;50:1020–8.
49. Griffiths CEM, et al. Dermatol Ther (Heidelb) 2022;12:1431–46.
50. Deodhar AA, et al. Ann Rheum Dis 2022;81:944–50.
51. Chandran V, et al. Rheumatology (Oxford). 2020;59(10):2774-2784.
52. Orbai AM, et al. Rheumatol Ther. 2021;8(1):199-217.
53. Kristensen LE, et al. Rheumatol Ther. 2022;9:109-125.
54. Deodhar AA, et al. BMC Rheumatol. 2021;5:35.
55. Rol da ANS. Disponível em: http://www.ans.gov.br/index.php/planosdesaudeeoperadoras/espacodoconsumidor/737-rol-deprocedimentos%3E . Acesso em: 19 nov. 2024.
56. Relatório de recomendação CONITEC. Disponível em: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2024/relatorio-preliminar-ixequizumabe-artrite-psoriasica-cp47 . Acesso em: 17 dez. 2024.
57. Kristensen LE, Ng KJ, Ngantcha M, et al. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open 2024:10:e004318. doi: 10.1136/rmdopen-2024-004318.